New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
- Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)
- These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company
COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023.
The results will be presented in two posters:
1. Title: “AI-designed personalized neoantigen vaccine, EVX-02, induces robust T-cell responses in melanoma patients”
Poster #: 623
Location: Exhibit Hall B – San Diego Convention Center
Time: Friday, November 3, 9 a.m. - 7 p.m. PDT
This poster will be presented by Evaxion’s senior project manager, Daniela Kleine-Kohlbrecher. The abstract was also selected by the SITC Communications Committee to be presented at the SITC 2023 Annual Meeting Press Conference, scheduled for Wednesday, November 1, from 12:00–1:30 p.m. PDT.
2. Title: “Effects of an AI-generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma. A clinical trial update”
Poster #: 782-H
Location: Exhibit Hall B – San Diego Convention Center
Time: Saturday, November 4, 9 a.m. - 8:30 p.m. PDT
This poster will be presented by principal investigator Professor Adnan Khattak from the Hollywood Private Hospital in Nedlands, Australia.
Christian Kanstrup, Chief Executive Officer at Evaxion, commented, “We are thrilled about the continuous buildup of positive clinical evidence for the unique predictive capabilities of our AI-immunology™ platform, which we believe holds promise for truly groundbreaking cancer treatments.”
Birgitte Rønø, Chief Scientific Officer at Evaxion, expressed her enthusiasm about the upcoming conference, stating, “We are looking forward to sharing these promising clinical trial results with the SITC community, showcasing the advantages of our AI-Immunology™ platform to design personalized cancer vaccines. We believe this takes us one step closer to bringing novel treatments to the market and meeting the pressing global medical need for cancer patients.”
About EVX-01 Phase 2 Clinical Trial
EVX-01 is Evaxion’s lead clinical asset and constitutes a peptide-based personalized cancer vaccine. The Phase 2 clinical study is a self-sponsored open-label, single-arm, multi-center trial carried out in collaboration with Merck Sharp & Dohme LLC, together with leading principal investigators and research centers from Italy and Australia, and aims at evaluating the efficacy and safety of EVX-01 vaccination in combination with anti-PD1 treatment (pembrolizumab) in treatment-naive patients with metastatic or unresectable malignant stage III or IV melanoma. More information can be accessed under clinical trial ID NCT05309421.
AboutEVX-02 Phase 1/2a Clinical Trial
The EVX-02 Phase 1/2a represents Evaxion’s first-in-human DNA-based personalized cancer vaccine study. This open-label, multi-center study aims at assessing the safety, tolerability, pharmacodynamic responses, and efficacy of EVX-02 neoantigen vaccine and anti-PD-1 treatment (nivolumab) in patients who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma with risk of recurrence. More information can be accessed under clinical trial ID NCT04455503.
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-immunology™ platform and vaccine pipeline, please visit our website.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sanoma Corporation - Managers' Transactions11.12.2023 09:15:00 CET | Press release
Sanoma Corporation, Managers’ Transactions, 11 December 2023 at 10:15 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Anna Herlin Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 45653/4/6 ____________________________________________ Transaction date: 2023-12-08 Venue: AQED Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 921 Unit price: 6.955 EUR Aggregated transactions (1): Volume: 921 Volume weighted average price: 6.955 EUR ____________________________________________ Transaction date: 2023-12-08 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1):
Ekstraordinære indfrielser (CK 93)11.12.2023 09:13:56 CET | pressemeddelelse
I medfør af kapitalmarkedsloven § 24, oplyser DLR Kredit hermed om ekstraordinære indfrielser pr. fredag den 08.december 2023. Oplysningerne fremgår af vedhæftede fil. Denne meddelelse er offentliggjort med henblik på opfyldelse af transparensdirektivets krav om offentliggørelse. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Spørgsmål kan rettes til: Head of Rating & IR Jakob Kongsgaard Olsson tlf. nr. 33 42 07 06. Med venlig hilsen DLR Kredit A/S Vedhæftet fil ck93-2023-12-08
Aktietilbagekøbsprogram - uge 4911.12.2023 09:13:51 CET | pressemeddelelse
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter Dato 11.12.2023 Aktietilbagekøbsprogram - uge 49 Aktietilbagekøbsprogrammet løber i perioden fra og med den 3. august 2023 til og med den 22. januar 2024. I denne periode vil Ringkjøbing Landbobank tilbagekøbe aktier for en maksimal markedsværdi af 385 mio. kroner under et aktietilbagekøbsprogram, jf. selskabsmeddelelse af 2. august 2023. Programmet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe Harbour”-reguleringen. Følgende transaktioner er foretaget under aktietilbagekøbsprogrammet: DatoAntal aktier (stk.)Gennemsnitlig købspris (kroner)Tilbagekøbt i alt under programmet (kroner)I alt i henhold til seneste meddelelse311.300986,63307.137.1204. december 20233.800942,703.582.2605. december 20233.400937,923.188.9286. december 20233.600936,493.371.3647. december 20233.500935,5
Share buy-back programme - week 4911.12.2023 09:13:51 CET | Press release
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 11.12.2023 Share buy-back programme - week 49 The share buy-back programme runs from and including 3 August 2023 up to and including 22 January 2024. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 385 million under a share buy-back programme, see company announcement of 2 August 2023. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme: DateNumber of sharesAverage purchase price (DKK)Total purchased under the programme (DKK)Total in accordance with the last announcement311,300986.63307,137,1204 December 20233,800942.703,582,2605 December 20233,400937.923,188,9286 December 20233,600936.493,371,3647 December 20233,500935.523,
NGS Group ABs dotterbolag Plus Care vinner återigen avtal med att bemanna Närhälsans Jourcentraler11.12.2023 09:00:00 CET | Pressemelding
NGS Group ABs dotterbolag Plus Care har blivit valda som den enda leverantören av läkarbemanning till Närhälsan Jourcentraler och Närhälsan Östra sjukhuset närakut, som täcker hela Västra Götalandsregionen (VGR). Det nya avtalet ger oss möjlighet att fortsätta vårt arbete med att stötta VGR i att patienter får vård under kvällar och helger. Plus Care har varit den enda upphandlade leverantören av läkare till dessa jourcentraler sedan vi tecknade vårt första avtal med VGR 2019. Detta har gjort det möjligt för oss att bygga upp en stark relation med, och djupgående kunskap kring, Närhälsan och därigenom garantera kontinuitet och kvalitet i vården. Från och med den 1 april 2024 kommer Plus Care att fortsätta bemanna totalt 12 jourlinjer runt omkring i Västra Götalandsregionen. Detta innebär att våra läkare kommer att vara tillgängliga varje dag, året runt, för att säkerställa att vårdbehovet hos patienterna blir tillgodosett. Vi är glada över att ha fått förtroendet att fortsätta detta vi